datetime,headline,summary,related,lang,source
2020-12-08 07:34:46-05:00,"Neurostimulation Devices Market Opportunities 2020 with Industry Size, Growth, Trends and Forecast by 2027 | Cyberonics, Boston Scientific Corporation, St. Jude Medical, Nevro Corporation",Global Neurostimulation Devices Market Analysis to 2025 is a specialized and in-depth study of the Neurostimulation Devices industry with a focus on the global market trend. The report aims to provide an overview of global Neurostimulation Devices Market with detailed,NVRO,en,OpenPR
2020-12-03 07:00:00-05:00,Nevro Announces Director Appointment,"REDWOOD CITY, Calif., Dec. 3, 2020 /PRNewswire/ -- Nevro Corp. (""Nevro"") (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, announced that Susan E. Siegel has been appointed as a member of the Board of…",NVRO,en,PR Newswire
2020-11-24 07:00:00-05:00,­Nevro to Participate in Citi Bank Head Shoulders Knees and Toes Conference Call Series on November 30th,"REDWOOD CITY, Calif., Nov. 24, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President will…",NVRO,en,PR Newswire
2020-11-20 07:46:50-05:00,Nevro (NYSE:NVRO) Upgraded by TheStreet to “C-“,"TheStreet upgraded shares of Nevro (NYSE:NVRO) from a d+ rating to a c- rating in a research report released on Wednesday, TheStreetRatingsTable reports. NVRO has been the topic of several other reports. Canaccord Genuity upped their price objective on shares of Nevro from $116.00 to $153.00 and gave the stock a buy rating in a […]",NVRO,en,Transcript Daily
2020-11-19 00:13:42-05:00,"Nerve Stimulator Market With Leading Players like Medtronic PLC, Cyberonics, Boston Scientific Corporation, St. Jude Medical, Nevro Corporation, ANM Adaptive Neuromodulation, BioControl Medical, Cerebomed, Neuronetics, Neuropace, Neuropace, Nevro","The electrical nerve stimulation procedure uses a nerve stimulator, which treats chronic pain with an electrical current. A nerve stimulator set at low intensity is used to monitor the status of relevant nerves to ensure they still transmit promptly and",NVRO,en,OpenPR
2020-11-17 16:02:00-05:00,Nevro Announces Abstract Presentations for PDN and NSRBP Trials Have Been Accepted for the Late Breaking Trials Plenary Session at NANS 2021 Conference,"REDWOOD CITY, Calif., Nov. 17, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, announced today that both data abstracts for Painful Diabetic Neuropathy (PDN) and…",NVRO,en,PR Newswire
2020-11-05 16:02:00-05:00,Nevro Announces Third Quarter 2020 Financial Results,"REDWOOD CITY, Calif., Nov. 5, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced its financial results for the third quarter ended September 30, 2020….",NVRO,en,PR Newswire
2020-11-05 10:52:00-05:00,Nevro Earnings Scorecard & Analyst Reports Stock market Insights & financial analysis,"Nevro announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…",NVRO,en,Stock Market Daily
2020-10-27 06:13:54-05:00,"Neurostimulation Devices Market Top Key Players- Medtronic plc, NeuroPace Inc., Nevro Corporation, Neuronetics Inc. Growth Trends, quantitative analysis Industry Analysis and Market Dynamics of the Global Market, 2020 to 2027","Summary of the Neurostimulation Devices Market Report Due to the various economic, technological, research & development and geographical aspects, the Neurostimulation Devices Market would gain a healthy CAGR and market size from 2020 to 2027. The growth trend would continue to",NVRO,en,OpenPR
2020-10-27 06:08:42-05:00,"Neurostimulation Devices Market Top Key Players- Nevro Corporation, Neuronetics Inc., NeuroSigma, Inc., Synapse Biomedical Inc Growth Trends, quantitative analysis Industry Analysis and Market Dynamics of the Global Market, 2020 to 2027","Summary of the Neurostimulation Devices Market Report Due to the various economic, technological, research & development and geographical aspects, the Neurostimulation Devices Market would gain a healthy CAGR and market size from 2020 to 2027. The growth trend would",NVRO,en,OpenPR
2020-10-24 01:44:49-05:00,Nevro (NYSE:NVRO) Raised to “Positive” at OTR Global,"OTR Global upgraded shares of Nevro (NYSE:NVRO) to a positive rating in a research report report published on Wednesday morning, The Fly reports. Several other research firms have also recently commented on NVRO. Oppenheimer initiated coverage on Nevro in a research note on Wednesday, August 5th. They issued a hold rating on the stock. SVB […]",NVRO,en,Stock Observer
2020-10-23 06:26:09-05:00,"The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 22) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Beam Therapeutics Inc (NASDAQ: BEAM ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunomedics, Inc. (NASDAQ: IMMU ) Kodiak Sciences Inc (NASDAQ: KOD ) Nevro Corp (NYSE: NVRO ) Praxis Precision Medicines Inc (NASDAQ: PRAX ) Repligen Corporation (NASDAQ: RGEN ) Replimune Group Inc (NASDAQ: REPL ) (priced its common stock offering of 4.69 million shares at $40 apiece. Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 22) Artelo Biosciences Inc (NASDAQ: ARTL ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Aziyo Biologics Inc (NASDAQ: AZYO ) DBV Technologies ADR Representing 0.5 Ord Shs (NASDAQ: DBVT ) FSD Pharma Inc (NASDAQ: HUGE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) (priced its $15 million worth of common stock offering) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Metacrine Inc (NASDAQ: MTCR ) Rockwell Medical Inc (NASDAQ: RMTI ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) Stocks In Focus Akebia Presents Positive Phase 3 Data For Anemia Drug In Chronic Kidney Disease Patients Akebia Therapeutics Inc (NASDAQ: AKBA ) presented at the American Society of Nephrology Kidney Week 2020 Reimagined, …","NVRO,NVIV",en,Benzinga
2020-10-22 15:05:00-05:00,Nevro to Report Third Quarter 2020 Financial Results,"REDWOOD CITY, Calif., Oct. 22, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the Company will release its financial results for the third quarter…",NVRO,en,PR Newswire
2020-10-22 06:44:51-05:00,Nevro (NYSE:NVRO) Upgraded to “Positive” at OTR Global,"OTR Global upgraded shares of Nevro (NYSE:NVRO) to a positive rating in a research note released on Wednesday, The Fly reports. Several other equities analysts have also recently weighed in on NVRO. ValuEngine raised Nevro from a hold rating to a buy rating in a report on Saturday, August 22nd. Robert W. Baird began coverage […]",NVRO,en, Dakota Financial News
2020-10-22 05:57:57-05:00,"Neurosurgery Devices Market Expected to Deliver Dynamic Progression until 2027 | Major Players , Boston Scientifi, Medtronic, Nevro Corporation, Adeor Medical, Karl Storz, Abbott","Rise in incidences and prevalence of neurological conditions within the population and the advantage of neurosurgery over other conventional surgeries are expected to boost the growth of the neurosurgery devices market across the globe. However, higher costs involved in neuro",NVRO,en,OpenPR
2020-10-20 11:58:42-05:00,Analysts Anticipate Nevro Corp. (NYSE:NVRO) Will Post Quarterly Sales of $103.56 Million,"Equities research analysts predict that Nevro Corp. (NYSE:NVRO) will announce $103.56 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Nevro’s earnings, with the lowest sales estimate coming in at $102.90 million and the highest estimate coming in at $105.00 million. Nevro posted sales of $100.16 million […]",NVRO,en,Transcript Daily
2020-10-20 11:58:42-05:00,Zacks: Brokerages Expect Nevro Corp. (NYSE:NVRO) Will Post Earnings of -$0.58 Per Share,"Brokerages predict that Nevro Corp. (NYSE:NVRO) will report earnings per share (EPS) of ($0.58) for the current quarter, according to Zacks. Six analysts have issued estimates for Nevro’s earnings. The lowest EPS estimate is ($0.94) and the highest is ($0.39). Nevro also posted earnings per share of ($0.58) in the same quarter last year. The […]",NVRO,en,Transcript Daily
2020-10-15 12:41:00-05:00,"Liberty All-Star® Growth Fund, Inc. September 2020 Monthly Update","BOSTON , Oct. 15, 2020 /PRNewswire/ -- Below is the September 2020 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG ) Liberty All-Star Growth Fund, Inc. Ticker: ASG Monthly Update, September, 2020 Investment Approach: Fund Style: All-Cap Growth Fund Strategy: Combines three growth style investment managers, each with a distinct capitalization focus (small-, mid- and large-cap) selected and continuously monitored by the Fund's Investment Advisor. Investment Managers: Weatherbie Capital, LLC Small-Cap Growth Congress Asset Management Company, LLP Mid-Cap Growth Sustainable Growth Advisers, LP Large-Cap Growth Top 20 Holdings at Month-End (31.5% of equity portfolio) 1 FirstService Corp. 2.1% 2 Chegg, Inc. 2.0% 3 Paylocity Holding Corp. 1.9% 4 Nevro Corp. 1.9% 5 Microsoft Corp. 1.7% 6 Visa, Inc. 1.7% 7 Progyny, Inc. 1.6% 8 Amazon.com, Inc. Full story available on Benzinga.com",NVRO,en,Benzinga
2020-10-15 07:03:43-05:00,"The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Treatment, Can Fite Issues Psoriasis Readout","Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 14) 10X Genomics Inc (NASDAQ: TXG ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Blueprint Medicines Corp (NASDAQ: BPMC ) Calliditas Therapeutics Adr Rep 2 Ord Shs (NASDAQ: CALT ) Cellectis SA (NASDAQ: CLLS ) Crispr Therapeutics AG (NASDAQ: CRSP ) Denali Therapeutics Inc (NASDAQ: DNLI ) Immunomedics, Inc (NASDAQ: IMMU ) - The Hart-Scott-Rodino waiting period for its impending acquisition by Gilead Sciences, Inc. (NASDAQ: GILD ) expired, meeting one of the conditions necessary for the consummation of the transaction Insulet Corporation (NASDAQ: PODD ) Kronos Bio Inc (NASDAQ: KRON ) (went public Friday) Kura Oncology Inc (NASDAQ: KURA ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mirati Therapeutics Inc (NASDAQ: MRTX ) NeoGenomics, Inc (NASDAQ: NEO ) Nevro Corp (NYSE: NVRO ) Novocure Ltd (NASDAQ: NVCR ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Oncorus Inc (NASDAQ: ONCR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) PRA Health Sciences Inc (NASDAQ: PRAH ) Replimune Group Inc (NASDAQ: REPL ) (abstract comprising data for its lead candidate RP1 in advanced solid tumors to be presented at the November Society for Immunotherapy of Cancer annual meeting made available online) Seres Therapeutics Inc (NASDAQ: MCRB ) SpringWorks Therapeutics Inc (NASDAQ: Full story available on Benzinga.","NVRO,NVCR",en,Benzinga
2020-10-13 07:20:13-05:00,"The Daily Biotech Pulse: J&J Pauses Coronavirus Vaccine Studies, Voyager's Huntington's Disease Study Placed On Hold, Altimmune Vaccine Data","Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 12) 10X Genomics Inc (NASDAQ: TXG ) Acceleron Pharma Inc (NASDAQ: XLRN ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) argenx SE – ADR (NASDAQ: ARGX ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Blueprint Medicines Corp (NASDAQ: BPMC ) Calliditas Therapeutics Adr Rep 2 Ord Shs (NASDAQ: CALT ) Cardiff Oncology Inc (NASDAQ: CRDF ) CareDx Inc (NASDAQ: CDNA ) Castle Biosciences Inc (NASDAQ: CSTL ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kronos Bio Inc (NASDAQ: KRON ) (went public Friday) Kura Oncology Inc (NASDAQ: KURA ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Lantern Pharma Inc.","NVRO,NVCR",en,Benzinga
2020-10-13 03:05:00-05:00,"Implantable Neurostimulators Market Size Worth $11.0 Billion By 2027 | CAGR: 11.7%: Grand View Research, Inc.","SAN FRANCISCO , Oct. 13, 2020 /PRNewswire/ -- The global implantable neurostimulators market size is anticipated to reach USD 11.0 billion by 2027, expanding at a CAGR of 11.7%, according to a new report by Grand View Research, Inc. Increasing incidence of neurological diseases and higher occurrence of associated chronic pain and discomfort are driving the market. Key suggestions from the report: On the basis of type, the spinal cord stimulators segment dominated the market with a share of 52.5% in 2019. As they are widely used in the non-malignant chronic neuropathic pain management which do not respond to pain medications Based on application, the pain management segment dominated the market with a share of 65.1% in 2019 owing to the high prevalence of chronic pain disorders such as disk surgery pain, migraine, limb and leg pain, particularly with the aging population North America dominated the market with the highest revenue share of 49.2% in 2019 owing to continuous product launches by key players in this region.",NVRO,en,Benzinga
2020-10-06 12:27:32-05:00,"Trending News-Global Electroceuticals Bioelectric Medicine Market 2020,(Impact of Covid-19), Share, Size,Trends and Future Opportunities till 2026 | Nevro Corporation, Biotronik, Sonova Holding AG","This report provides a detailed analysis of the Electroceuticals Bioelectric Medicine market, provides meaningful insights into the market, based on facts and data available previously. The report provides information on the products/services, along with discussing the various end-user industries where",NVRO,en,OpenPR
2020-10-06 03:06:53-05:00,"Global Transcutaneous Electrical Nerve Stimulators Market Taking an Unexpected Growth Rate towards the Forecast Year 2026||Medtronic, Nevro Corp., NeuroMetrix, Inc., Abbott, Uroplasty Inc., Cogentix Medical, Zynex MedicalCochlear Ltd","“Global Transcutaneous Electrical Nerve Stimulators Market–Industry Trends and Forecast to 2026” Comprehensive Research Report to Added In Databridgemarketresearch.com directory. Report carrying 350 pages, 60 Figures And 220 Tables in it. Global Transcutaneous Electrical Nerve StimulatorsMarket Statistical Overview Report 2018 gives","NVRO,NURO",en,OpenPR
2020-10-05 01:43:16-05:00,Nevro chief faces fraud claims,"The ex-Australian head of a medical device company allegedly admitted he had made ""a terrible mistake"" when he was confronted with doctored invoices and money funneled to his wife's business.",NVRO,en,The Australian Financial Review
2020-10-01 14:28:34-05:00,"Neuromodulation Market Insights 2020 - Sector Overview, Competitive Players and Forecast To 2027| Cyberonics, Inc., ST. Jude Medical, Inc., Neurosigma, Inc., Nevro Corporation, Biocontrol Medical, etc",The Global Neuromodulation Market research report published by Reports and Data provides an in-depth analysis of the Neuromodulation industry and its economic landscape for businesses that offers insightful data about profitability and development for the prominent players in the Neuromodulation,NVRO,en,OpenPR
2020-09-17 06:59:47-05:00,"The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO","Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Myokardia Inc (NASDAQ: MYOK ) Nevro Corp (NYSE: NVRO ) Novocure Ltd (NASDAQ: NVCR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Revance Therapeutics Inc (NASDAQ: RVNC ) SI-Bone Inc (NASDAQ: SIBN ) Silk Road Medical Inc (NASDAQ: SILK ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 16) PainReform Ltd (NASDAQ: PRFX ) Pandion Therapeutics Inc (NASDAQ: PAND ) SILENCE THERAPE/S ADR (NASDAQ: SLN ) Stocks In Focus Moderna Announces 2 R&D Collaborations For Up To $880M Moderna Inc (NASDAQ: MRNA ) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) announced a three-year strategic research collaboration and licensing agreement aimed at the discovery and development of lipid nanoparticles and mRNAs for the delivery of gene-editing therapies for cystic fibrosis.","NVTA,NVRO,NVCR",en,Benzinga
2020-09-14 06:00:00-05:00,Nevro Initiates Plan for Manufacturing Operations in Costa Rica to Support Future Growth,"REDWOOD CITY, Calif., Sept. 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that it will establish global manufacturing operations in Costa Rica to…",NVRO,en,PR Newswire
2020-09-01 06:00:00-05:00,Nevro to Present at Upcoming Conferences,"REDWOOD CITY, Calif., Sept. 1, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present…",NVRO,en,PR Newswire
2020-08-14 16:41:00-05:00,"Liberty All-Star® Growth Fund, Inc. July 2020 Monthly Update","BOSTON , Aug. 14, 2020 /PRNewswire/ -- Below is the July 2020 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG ) Liberty All-Star Growth Fund, Inc. Ticker: ASG Monthly Update, July, 2020 Investment Approach: Fund Style: All-Cap Growth Fund Strategy: Combines three growth style investment managers, each with a distinct capitalization focus (small-, mid- and large-cap) selected and continuously monitored by the Fund's Investment Advisor. Investment Managers: Weatherbie Capital, LLC Small-Cap Growth Congress Asset Management Company, LLP Mid-Cap Growth Sustainable Growth Advisers, LP Large-Cap Growth Top 20 Holdings at Month-End (31.0% of equity portfolio) 1 Chegg, Inc. 2.3% 2 FirstService Corp. 2.1% 3 Nevro Corp. 1.9% 4 Paylocity Holding Corp. 1.7% 5 Microsoft Corp. 1.7% 6 Visa, Inc. 1.6% 7 Facebook, Inc. 1.6% 8 Amazon.com, Inc. 1.6% 9 Progyny, Inc. 1.5% 10 Casella Waste Systems, Inc. Full story available on Benzinga.com",NVRO,en,Benzinga
2020-08-10 06:59:00-05:00,"Global Nerve Repair and Regeneration Market Outlook 2020: Company Profiles of Key Players Axogen, Baxter, Nevro, Nuvectra, Polyganics and Stryker - ResearchAndMarkets.com","DUBLIN--(BUSINESS WIRE)--The ""Nerve Repair and Regeneration - Global Market Outlook (2018-2027)"" report has been added to ResearchAndMarkets.com's offering. The Global Nerve Repair and Regeneration market accounted for $6.46 billion in 2018 and is expected to reach $21.68 billion by 2027 growing at a CAGR of 14.4% during the forecast period. Some of the key factors propelling the market growth are technological developments for nerve repair and regeneration and an increase in healthcare expense",NVRO,en,Business Wire
2020-08-07 06:00:00-05:00,Nevro to Present at Canaccord Genuity 40th Annual Virtual Growth Conference,"REDWOOD CITY, Calif., Aug. 7, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present…",NVRO,en,PR Newswire
2020-06-04 10:31:31-05:00,Why Is Nevro (NVRO) Up 7.1% Since Last Earnings Report?,Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,NVRO,en,Zacks Investment Research
2020-06-04 06:00:00-05:00,Nevro Appoints Finance Executive Roderick MacLeod as Chief Financial Officer,"REDWOOD CITY, Calif., June 4, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the appointment of Roderick (""Rod"") MacLeod as Chief Financial Officer,…",NVRO,en,PR Newswire
2020-05-18 00:59:00-05:00,Nevro's (NVRO) Senza Omnia SCS System Gets CE Mark Approval,"Nevro (NVRO) received CE mark approval for the Senza Omnia SCS system, which is likely to boost its international presence.",NVRO,en,Zacks Investment Research
2020-05-14 06:00:00-05:00,Nevro Announces CE Mark Approval of Senza® Omnia™ Spinal Cord Stimulation System to Treat Chronic Pain,"REDWOOD CITY, Calif., May 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced it has received CE mark approval for the Senza® Omnia™ Spinal Cord…",NVRO,en,PR Newswire
2020-05-07 08:14:00-05:00,Nevro (NVRO) Earnings and Revenues Beat Estimates in Q1,Nevro's (NVRO) domestic revenues improved on a year-over-year basis in Q1.,NVRO,en,Zacks Investment Research
2020-05-04 06:00:00-05:00,Nevro To Participate in Upcoming May Conferences,"REDWOOD CITY, Calif., May 4, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that Nevro Chairman, CEO and President D. Keith Grossman is scheduled to…",NVRO,en,PR Newswire
2020-04-28 11:33:32-05:00,Will Nevro (NVRO) Report Negative Earnings Next Week? What You Should Know,Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,NVRO,en,Zacks Investment Research
2020-04-21 06:00:00-05:00,Nevro to Report First Quarter 2020 Financial Results,"REDWOOD CITY, Calif., April 21, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the Company will release its financial results for the first…",NVRO,en,PR Newswire
2020-04-03 15:44:00-05:00,Nevro Announces the Full Exercise of the Underwriter's Option to Purchase Additional Common Stock and the Underwriter's Over-allotment Option to Purchase Additional Convertible Senior Notes,"REDWOOD CITY, Calif., April 3, 2020 /PRNewswire/ -- Nevro Corp. (""Nevro"") (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the underwriter of each of Nevro's previously announced…",NVRO,en,PR Newswire
2020-04-03 07:30:00-05:00,Nevro (NVRO) Looks Good: Stock Adds 6.5% in Session,"Nevro (NVRO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.",NVRO,en,Zacks Investment Research
2020-04-02 16:05:17-05:00,"Walgreens, Shopify fall; Occidental, Nevro rise","Stocks that moved heavily or traded substantially on Thursday: Walgreens, Shopify fall; Occidental, Nevro rise",NVRO,en,ABC News
2020-04-02 06:57:45-05:00,"The Daily Biotech Pulse: Novartis Scraps Deal To Sell Sandoz Assets, Nevro Pre-Announces Q1 Shortfall, Affimed Granted Orphan Drug Designation","Here's a roundup of top developments in the biotech space over the last 24 hours. On a day when the three major averages shed over 4% in reaction to bleak forecasts concerning the COVID-19 pandemic's impact, none of the Nasdaq- or NYSE-listed biotech stocks hit 52-week highs or lows. Stocks In Focus InVitae Withdraws FY20 Guidance Due To Pandemic, Plans Offering InVitae Corp (NYSE: NVTA ), a medical genetics company, pre-announced first-quarter results and said it expects revenue of more than $63 million, up 55% year-over-year, billable tests of 147,000, up 65%, and non-GAAP cash burn of less than $100 million. Analysts expect revenue of $60.3 million. Citing the unknown duration and extent of COVID-19's impact on its business and the health care system in general, the company said it is withdrawing its guidance for 2020. Separately, the company announced an underwritten public offering of 17.78 million shares priced at $9 per share. All the shares are being sold by the company. The company expects the offering to close April 6 and to raise gross proceeds of about $16 million.","NVS,NVRO",en,Benzinga
2020-03-26 10:30:35-05:00,Why Is Nevro (NVRO) Down 34.3% Since Last Earnings Report?,Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,NVRO,en,Zacks Investment Research
2020-02-27 07:35:07-05:00,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy","The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Inspire Medical Systems Inc (NYSE: INSP ) (reacted to fourth-quarter results) Mersana Therapeutics Inc (NASDAQ: MRSN ) Moderna Inc (NASDAQ: MRNA ) Nevro Corp (NYSE: NVRO ) (announced fourth-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Revolution Medicines Inc (NASDAQ: RVMD ) Vir Biotechnology Inc (NASDAQ: VIR ) (announced a collaboration with WuXi Biologics for the development of antibodies to treat COVID-19) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Auris Medical Holding Ltd (NASDAQ: EARS )(announced publication of results of a study showing anti-epileptic and anti-convulsive activity of betahistine in a mouse model) Blueprint Medicines Corp (NASDAQ: BPMC ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Curis, Inc. (NASDAQ: CRIS ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galectin Therapeutics Inc.",NVRO,en,Benzinga
2020-02-25 21:00:38-05:00,Nevro Corp (NVRO) Q4 2019 Earnings Call Transcript | The Motley Fool,"NVRO earnings call for the period ending December 31, 2019.",NVRO,en,The Motley Fool
2020-02-25 16:17:13-05:00,"Nevro EPS beats by $0.19, beats on revenue",Nevro (NYSE:NVRO): Q4 GAAP EPS of -$0.44 beats by $0.19. Revenue of $114.37M (+6.0% Y/Y) beats by $2.57M. Press Release,NVRO,en,Seeking Alpha
2020-02-20 07:06:25-05:00,"The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Arcus Biosciences Inc (NYSE: RCUS ) Ascendis Pharma A/S (NASDAQ: ASND ) AVITA MED LTD/S ADR (NASDAQ: RCEL )(reacted to its half-yearly results) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) ChemoCentryx Inc (NASDAQ: CCXI ) Cue Biopharma Inc (NASDAQ: CUE )(said its therapeutic Immuno-STAT platform will be featured in a Merck & Co., Inc.'s (NYSE: MRK ) presentation at the Antigen Specific Immune Tolerance Drug Development Summit) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB )(reacted to its quarterly and full-year results) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Insulet Corporation (NASDAQ: PODD ) Intuitive Surgical, Inc.",NVRO,en,Benzinga
2020-02-16 09:04:00-05:00,US company provided kickbacks to doctors in Switzerland,US medical device company Nevro promised to pay doctors in Switzerland if they used the company’s spinal cord stimulation system.,NVRO,en,Swiss Info
2020-02-14 18:17:11-05:00,Nevro : Annual Statement of Changes in Beneficial Ownership | MarketScreener,"FORM 5 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1. [… | February 15, 2020",NVRO,en,MarketScreener
2020-02-14 08:23:03-05:00,"The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering","The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex Life Sciences Corp (NASDAQ: AVXL ) AtriCure Inc. (NASDAQ: ATRC ) Beam Therapeutics Inc (NASDAQ: BEAM ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) ChemoCentryx Inc (NASDAQ: CCXI ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fortress Biotech (NASDAQ: FBIO ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Masimo Corporation (NASDAQ: MASI ) NeoGenomics, Inc. (NASDAQ: NEO ) Nevro Corp (NYSE: NVRO ) Recro Pharma Inc (NASDAQ: REPH ) ResMed Inc. (NYSE: RMD ) Revolution Medicines Inc (NASDAQ: RVMD ) (went public Thursday) Syneos Health Inc (NASDAQ: SYNH ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) Taro Pharmaceutical Industries Ltd. (NYSE: TARO ) West Pharmaceutical Services Inc.",NVRO,en,Benzinga Feeds
2020-02-12 09:18:32-05:00,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV ) Acceleron Pharma Inc (NASDAQ: XLRN ) Agile Therapeutics Inc (NASDAQ: AGRX )( announced securing of loan facility) Allergan plc (NYSE: AGN ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) AVITA MED LTD/S ADR (NASDAQ: RCEL ) ChemoCentryx Inc (NASDAQ: CCXI ) Cue Biopharma Inc (NASDAQ: CUE ) Cytokinetics, Inc. (NASDAQ: CYTK ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Insulet Corporation (NASDAQ: PODD ) Masimo Corporation (NASDAQ: MASI ) Medpace Holdings Inc (NASDAQ: MEDP ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Nevro Corp (NYSE: NVRO ) Novartis AG (NYSE: NVS )(announced priority review for its lung cancer drug) Pacira Biosciences Inc (NASDAQ: PCRX ) PAVmed Inc (NASDAQ: PAVM )(PAVmed's EsoGuard Esophageal DNA test was accorded Breakthrough Device designation) Penumbra Inc (NYSE: PEN ) Principia Biopharma Inc (NASDAQ: PRNB ) PTC Therapeutics, Inc (NASDAQ: PTCT ) Seattle Genetics, Inc. (NASDAQ: SGEN )(announced positive data readout for ADC in bladder cancer) Syneos Health Inc (NASDAQ: SYNH ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) West Pharmaceutical Services Inc. (NYSE: WST ) Zai Lab Ltd (NASDAQ: ZLAB ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Feb. 11) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) Brickell Biotech Inc (NASDAQ: BBI ) Endologix, Inc. (NASDAQ: ELGX ) Enzo Biochem, Inc. (NYSE: ENZ )( received New York State approval for its gynecological …","NVS,NVRO",en,Benzinga
2020-02-03 07:00:00-05:00,­Nevro to Report Fourth Quarter and Full Year 2019 Financial Results,"REDWOOD CITY, Calif., Feb. 3, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the Company will release its financial results for the fourth quarter…",NVRO,en,PR Newswire
2020-01-30 09:26:49-05:00,"The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 29) 10X Genomics Inc (NASDAQ: TXG ) Agile Therapeutics Inc (NASDAQ: AGRX ) Aptose Biosciences Inc (NASDAQ: APTO ) Catalent Inc (NYSE: CTLT ) Cabaletta Bio Inc (NASDAQ: CABA )(announced grant of orphan drug designation for its DSG3-CAART for the treatment of pemphigus vulgaris) AtriCure Inc. (NASDAQ: ATRC ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Fate Therapeutics Inc (NASDAQ: FATE ) Hologic, Inc. (NASDAQ: HOLX ) Insulet Corporation (NASDAQ: PODD ) Johnson & Johnson (NYSE: JNJ )(confirmed it is working on treatment/vaccines for coronavirus) Nevro Corp (NYSE: NVRO ) Profound Medical Corp (NASDAQ: PROF ) Quest Diagnostics Inc (NYSE: DGX ) ResMed Inc. (NYSE: RMD ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA )(reacted to publication of positive data readout for its lead drug candidate) Tandem Diabetes Care Inc (NASDAQ: TNDM ) West Pharmaceutical Services Inc. (NYSE: WST ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Jan. 29) Avanos Medical Inc (NYSE: AVNS ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Endologix, Inc. (NASDAQ: ELGX ) Galectin Therapeutics Inc.",NVRO,en,Benzinga
2020-01-29 08:30:46-05:00,"The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 28) 10X Genomics Inc (NASDAQ: TXG ) Acceleron Pharma Inc (NASDAQ: XLRN ) ( announced positive Phase 2 results for its pulmonary hypertension drug) Agile Therapeutics Inc (NASDAQ: AGRX ) AtriCure Inc. (NASDAQ: ATRC ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Catalent Inc (NYSE: CTLT ) Hologic, Inc. (NASDAQ: HOLX ) Insulet Corporation (NASDAQ: PODD ) Johnson & Johnson (NYSE: JNJ ) NeoGenomics, Inc. (NASDAQ: NEO ) Nevro Corp (NYSE: NVRO ) Profound Medical Corp (NASDAQ: PROF ) Quest Diagnostics Inc (NYSE: DGX ) Rapt Therapeutics Inc (NASDAQ: RAPT ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) SI-Bone Inc (NASDAQ: SIBN ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB )(H.C. Wainwright reiterated a Buy rating on shares) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Jan. 28) Correvio Pharma Corp (NASDAQ: CORV ) Endologix, Inc. (NASDAQ: ELGX ) Galectin Therapeutics Inc. (NASDAQ: GALT ) Heat Biologics Inc (NASDAQ: HTBX ) Neuronetics Inc (NASDAQ: STIM ) REDHILL BIOPHAR/S ADR (NASDAQ: RDHL ) Salarius Pharmaceuticals Inc (NASDAQ: SLRX ) X4 Pharmaceuticals Inc (NASDAQ: XFOR ) VIVUS, Inc. (NASDAQ: VVUS ) Stocks In Focus Novartis Q4 Sales, Core Income Rise, Guides to Sales, Earnings Growth Novartis AG (NYSE: NVS ) said its fourth-quarter sales rose 8% to $12.403 million, up 8% year-over-year.","NVS,NVRO",en,Benzinga
2020-01-28 07:12:23-05:00,"The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 27) 10X Genomics Inc (NASDAQ: TXG ) Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN )(announced early termination of waiting period for its proposed acquisition by Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN )) Cidara Therapeutics Inc (NASDAQ: CDTX ) Cleveland BioLabs, Inc. (NASDAQ: CBLI )(saw a coronavirus-induced rally ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY )(reacted to its Q3 results) Inovio Pharmaceuticals Inc (NASDAQ: INO )(announced Nevro Corp (NYSE: NVRO ) Oyster Point Pharma Inc (NASDAQ: OYST ) Quest Diagnostics Inc (NYSE: DGX ) Rapt Therapeutics Inc (NASDAQ: RAPT ) SI-Bone Inc (NASDAQ: SIBN ) Vaccinex Inc (NASDAQ: VCNX ) Vir Biotechnology Inc (NASDAQ: VIR ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Jan. 27) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Avanos Medical Inc (NYSE: AVNS ) Blueprint Medicines Corp (NASDAQ: BPMC ) Correvio Pharma Corp (NASDAQ: CORV ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Heat Biologics Inc (NASDAQ: HTBX ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) Kura Oncology Inc (NASDAQ: KURA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) MediciNova, Inc.",NVRO,en,Benzinga
2020-01-24 07:43:17-05:00,"The Daily Biotech Pulse: FDA Nod For Epizyme, Sonoma Explores Options For Dermatology Business, Roche's Cancer Drug Flunks Study","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 23) Baudax Bio Inc (NASDAQ: BXRX ) Mesoblast limited (NASDAQ: MESO ) Nevro Corp (NYSE: NVRO ) Oyster Point Pharma Inc (NASDAQ: OYST ) Soligenix, Inc. (NASDAQ: SNGX ) Syneos Health Inc (NASDAQ: SYNH ) TELA Bio Inc (NASDAQ: TELA ) Trillium Therapeutics Inc (NASDAQ: TRIL ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) Zai Lab Ltd (NASDAQ: ZLAB ) Down In The Dumps (Biotech stocks hitting 52-week lows on Jan. 23) Avanos Medical Inc (NYSE: AVNS ) Blueprint Medicines Corp (NASDAQ: BPMC ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Evolus Inc (NASDAQ: EOLS ) Kura Oncology Inc (NASDAQ: KURA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Second Sight Medical Products Inc (NASDAQ: EYES ) Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ) Therapix Biosciences Ltd – ADR (NASDAQ: TRPX ) Related Link: 7 Blockbuster Drugs Expected To Be Launched In 2020 Stocks In Focus Kura Oncology Announces Departure of Chief Medical Officer Kura Oncology said Antonio Gualberto, serving as Head of Development and Chief Medical Officer, will leave to pursue other opportunities.",NVRO,en,Benzinga
2020-01-23 07:24:36-05:00,"The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 22) 10X Genomics Inc (NASDAQ: TXG ) Abbott Laboratories (NYSE: ABT )(reported strong fourth-quarter results and issued in-line guidance) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) AtriCure Inc. (NASDAQ: ATRC ) BIO-TECHNE Corp (NASDAQ: TECH ) Bristol-Myers Squibb Co (NYSE: BMY ) Cardiovascular Systems Inc (NASDAQ: CSII ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Eli Lilly And Co (NYSE: LLY ) Fortress Biotech (NASDAQ: FBIO ) Horizon Therapeutics PLC (NASDAQ: HZNP )( received FDA nod for its thyroid eye disease drug) Insulet Corporation (NASDAQ: PODD ) Medtronic PLC (NYSE: MDT ) Masimo Corporation (NASDAQ: MASI ) Medpace Holdings Inc (NASDAQ: MEDP ) Nevro Corp (NYSE: NVRO ) Novocure Ltd (NASDAQ: NVCR )(announced coverage in Israel for its Optune in combination with temozolomide for the treatment of newly-diagnosed glioblastoma) Prevail Therapeutics Inc (NASDAQ: PRVL ) Repligen Corporation (NASDAQ: RGEN ) ResMed Inc. (NYSE: RMD ) Selecta Biosciences Inc (NASDAQ: SELB ) SI-Bone Inc (NASDAQ: SIBN ) Soligenix, Inc.","NVCR,NVRO",en,Benzinga
2020-01-22 07:00:00-05:00,Nevro to Present New Clinical Evidence at the 23rd Annual North American Neuromodulation (NANS) Society Meeting,"REDWOOD CITY, Calif., Jan. 22, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of the Company's HF10™…",NVRO,en,PR Newswire
2020-01-20 07:00:00-05:00,"Nevro Names Donald A. Middlebrook to Lead Clinical, Regulatory and Quality","REDWOOD CITY, Calif., Jan. 20, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that Donald A. Middlebrook has been named Vice President, Clinical,…",NVRO,en,PR Newswire
2020-01-16 04:14:00-05:00,Nevro (NVRO) Gains Ground on Solid Preliminary Q4 Results,Higher revenues and upbeat 2020 worldwide revenue outlook benefit Nevro's (NVRO) preliminary Q4 results.,NVRO,en,Zacks Investment Research
2020-01-14 07:00:00-05:00,Nevro Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Revenue,"REDWOOD CITY, Calif., Jan. 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced its preliminary unaudited revenue for the fourth quarter and year ended…",NVRO,en,PR Newswire
2020-01-10 07:00:00-05:00,Nevro to Host Investor Briefing at North American Neuromodulation Society (NANS) 2020 Conference,"REDWOOD CITY, Calif., Jan. 10, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that it will host and webcast an investor briefing at the North American…",NVRO,en,PR Newswire
2020-01-09 08:39:54-05:00,"The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results","The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 8.) Allergan plc (NYSE: AGN ): AbbVie Inc (NYSE: ABBV ) announced plans to integrate Allergan, which it has agreed to acquire Applied Therapeutics Inc (NASDAQ: APLT ) ( announced positive results for the midstage study of its experimental drug to treat inherited galactose processing disorder) Collegium Pharmaceutical Inc (NASDAQ: COLL ) (announced upbeat guidance for fiscal year 2020) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Dermira Inc (NASDAQ: DERM ) DexCom, Inc. (NASDAQ: DXCM ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Inspire Medical Systems Inc (NYSE: INSP ) Medtronic PLC (NYSE: MDT ) Nevro Corp (NYSE: NVRO ) NuVasive, Inc. (NASDAQ: NUVA ) (SunTrust initiated coverage of the stock with a Buy rating) PTC Therapeutics, Inc. (NASDAQ: PTCT ) Syneos Health Inc (NASDAQ: SYNH ) TG Therapeutics Inc (NASDAQ: TGTX ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Zoetis Inc (NYSE: ZTS ) None of the NYSE- or Nasdaq-listed biotech hit 52-week lows Wednesday.","NUVA,NVRO",en,Benzinga
2020-01-07 07:57:46-05:00,"The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering","The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 6.) Agile Therapeutics Inc (NASDAQ: AGRX ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Audentes Therapeutics Inc (NASDAQ: BOLD ) BioNTech SE – ADR (NASDAQ: BNTX ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Inspire Medical Systems Inc (NYSE: INSP ) Nevro Corp (NYSE: NVRO ) Nymox Pharmaceutical Corp (NASDAQ: NYMX ) (announced publication of a peer reviewed research report on the experimental studies for its fexapotide triflutate treatment for prostate enlargement and low-grade prostate cancer) Orthopediatrics Corp (NASDAQ: KIDS ) (announced sale of its adult Vilex business in Tennessee to Squadron Capital and used the proceeds for the repayment of term loan due to Squadron) Oyster Point Pharma Inc (NASDAQ: OYST ) Sanofi SA (NASDAQ: SNY ) (JPMorgan upgraded the shares from Neutral to Overweight, citing an attractive valuation) Soligenix, Inc.",NVRO,en,Benzinga
2020-01-03 07:55:22-05:00,"The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 2) Agile Therapeutics Inc (NASDAQ: AGRX (announced the appointment of healthcare industry veteran Kimberly Whelan as VP, Market Access, as it prepares for a potential Twirla commercial launch) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied Therapeutics Inc (NASDAQ: APLT ) Ascendis Pharma A/S (NASDAQ: ASND ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Cassava Sciences Inc (NASDAQ: SAVA ) ChemoCentryx Inc (NASDAQ: CCXI ) DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT ) Epizyme Inc (NASDAQ: EPZM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fortress Biotech (NASDAQ: FBIO ) INNATE PHARMA S/S ADR (NASDAQ: IPHA )( announced EMA acceptance of regulatory application for drug to treat hairy cell leukemia) The Medicines Company (NASDAQ: MDCO ) Mesoblast limited (NASDAQ: MESO )(announced submission of safety and efficacy data as part of rolling BLA submission for remestemcell-L for the treatment of children with steroid-refractory acute graft versus host disease) Mirati Therapeutics Inc (NASDAQ: MRTX ) Nevro Corp (NYSE: NVRO ) NuVasive, Inc. (NASDAQ: NUVA ) Otonomy Inc (NASDAQ: OTIC ) Syneos Health Inc (NASDAQ: SYNH ) Urovant Sciences Ltd (NASDAQ: UROV ) Veru Inc (NASDAQ: VERU ) West Pharmaceutical Services Inc. (NYSE: WST ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech stocks hitting 52-week lows on Jan. 2) Alterity Therapeutics Ltd (NASDAQ: ATHE ) Evelo Biosciences Inc (NASDAQ: EVLO ) Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Wave Life Sciences Ltd (NASDAQ: WVE ) Xeris Pharmaceuticals Inc (NASDAQ: XERS ) Stocks In Focus Acorda Gains After Hedge Fund Hikes Stake Acorda Therapeutics …","NUVA,NVRO",en,Benzinga
2019-12-26 07:55:50-05:00,"The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares","The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 24.) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Cassava Sciences Inc (NASDAQ: SAVA ) ChemoCentryx Inc (NASDAQ: CCXI ) Clearside Biomedical Inc (NASDAQ: CLSD ) DURECT Corporation (NASDAQ: DRRX ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Exagen Inc (NASDAQ: XGN ) Forty Seven Inc (NASDAQ: FTSV ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) HEALTH SCIENCES/SH (NASDAQ: IMVT ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Kodiak Sciences Inc (NASDAQ: KOD ) (JPMorgan initiated coverage with an Outperform rating) Microbot Medical Inc (NASDAQ: MBOT ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc.","NUVA,NVRO",en,Benzinga
2019-12-19 07:00:00-05:00,Nevro to Present at the 38th Annual J.P. Morgan Healthcare Conference,"REDWOOD CITY, Calif., Dec. 19, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present…",NVRO,en,PR Newswire
2019-11-26 08:06:41-05:00,"The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug","Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) (Guggenheim initiated coverage of stock with Buy rating and $50 price target) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) (announced achievement of enrollment target in a Phase 3 trial of drug to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) BioNTech SE – ADR (NASDAQ: BNTX ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Epizyme Inc (NASDAQ: EPZM ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Globus Medical Inc (NYSE: GMED ) Halozyme Therapeutics, Inc.","NVS,NVRO,NVIV",en,Benzinga
2019-11-11 23:18:59-05:00,Nevro (NYSE:NVRO) Price Target Raised to $80.00,"Nevro (NYSE:NVRO) had its price objective increased by JPMorgan Chase & Co. from $62.00 to $80.00 in a research note published on Thursday morning, Stock Target Advisor reports. JPMorgan Chase & Co. currently has a neutral rating on the medical equipment provider’s stock. Several other brokerages have also recently weighed in on NVRO. Canaccord Genuity […]",NVRO,en,Modern Readers
2019-11-08 09:15:00-05:00,"Nevro (NVRO) Q3 Loss Narrower Than Expected, Revenues Up Y/Y",Nevro (NVRO) launches the Senza Omnia SCS System commercially in the United States in Q3.,NVRO,en,Zacks Investment Research
2019-11-08 09:04:52-05:00,Morgan Stanley Raises Nevro (NYSE:NVRO) Price Target to $100.00,"Nevro (NYSE:NVRO) had its target price upped by analysts at Morgan Stanley from $76.00 to $100.00 in a research note issued on Thursday, Stock Target Advisor reports. The brokerage currently has an “overweight” rating on the medical equipment provider’s stock. Morgan Stanley’s price objective indicates a potential downside of 3.27% from the stock’s current price. […]",NVRO,en,Modern Readers
2019-11-06 16:10:00-05:00,Nevro Reports Third Quarter 2019 Financial Results,"REDWOOD CITY, Calif., Nov. 6, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported financial results for the third quarter ended September 30, 2019. Revenue…",NVRO,en,PR Newswire
2019-11-05 07:00:00-05:00,Nevro Announces U.S. Launch of Senza® Omnia™ Spinal Cord Stimulation System to Treat Chronic Pain,"REDWOOD CITY, Calif., Nov. 5, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced it has received approval from the U.S. Food and Drug Administration (FDA) for…",NVRO,en,PR Newswire
2019-09-13 06:40:02-05:00,"The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 11) Ardelyx Inc (NASDAQ: ARDX ) Avedro Inc (NASDAQ: AVDR ) Celgene Corporation (NASDAQ: CELG ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Enlivex Therapeutics Ltd (NASDAQ: ENLV ) The Medicines Company (NASDAQ: MDCO ) Medtronic PLC (NYSE: MDT ) Nevro Corp (NYSE: NVRO ) Radius Health Inc (NASDAQ: RDUS ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 11) CELYAD SA/ADR (NASDAQ: CYAD ) Endologix, Inc. (NASDAQ: ELGX ) Myovant Sciences Ltd (NYSE: MYOV ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) Karuna Therapeutics Inc (NASDAQ: KRTX ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP )(filed for a $12 million secondary offering) Tocagen Inc (NASDAQ: TOCA )( reported that its late-stage brain cancer study did not meet the primary endpoint) Trinity Biotech plc (NASDAQ: TRIB ) Stocks In Focus Ardelyx Gets FDA Nod For Constipation Drug Ardelyx announced the FDA has approved its tenapanor, brand name Ibsrela, a 50mg twice-daily oral pill for the treatment of irritable bowel syndrome with constipation in adults.",NVRO,en,Benzinga
2019-09-12 06:38:39-05:00,"The Daily Biotech Pulse: Ardelyx Awaits Ruling On Constipation Drug, Double Dose Of Good News For Roche, Tocagen Flunks Brain Cancer Study","The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 11.) Avedro Inc (NASDAQ: AVDR ) Catalyst Pharmaceuticals Inc (NASDAQ: CPRX ) Nevro Corp (NYSE: NVRO ) Down In The Dumps (Biotech stocks that hit 52-week lows Sept. 11.) Karuna Therapeutics Inc (NASDAQ: KRTX ) Stocks In Focus Roche Reports Positive Results For Two Drugs Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY ) announced full results from a pivotal Phase 3 study of satralizumab as a monotherapy for neuromyelitis optica spectrum disorder, or NMOSD, which showed that the investigational compound achieved a 55% reduction in the risk of relapses compared to placebo. The results were presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis being held in Stockholm, Sweden. In the large subgroup of patients seropositive for AQP4-IgG antibodies, a 74% reduction in the risk of relapses occurred.",NVRO,en,Benzinga
2019-09-07 08:30:44-05:00,Why Is Nevro (NVRO) Up 37.7% Since Last Earnings Report?,Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,NVRO,en,Zacks Investment Research
2019-08-22 06:18:53-05:00,"The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 21) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) AstraZeneca plc (NYSE: AZN )(advanced despite reporting negative results for its lung cancer drug) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Cardiovascular Systems Inc (NASDAQ: CSII ) DexCom, Inc. (NASDAQ: DXCM ) Lipocine Inc (NASDAQ: LPCN ) NextCure Inc (NASDAQ: NXTC ) Nevro Corp (NYSE: NVRO ) Novocure Ltd (NASDAQ: NVCR ) Recro Pharma Inc (NASDAQ: REPH ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 21) Abeona Therapeutics Inc (NASDAQ: ABEO ) Artelo Biosciences Inc (NASDAQ: ARTL ) Avanos Medical Inc (NYSE: AVNS ) CAN-FITE BIOPHA/S ADR (NYSE: CANF ) KemPharm Inc (NASDAQ: KMPH ) Meridian Bioscience, Inc. (NASDAQ: VIVO ) Nektar Therapeutics (NASDAQ:NKT) Obalon Therapeutics Inc (NASDAQ: OBLN ) STRATA Skin Sciences Inc (NASDAQ: SSKN ) Stocks In Focus ViiV's Long-Acting HIV Drug Combo Aces Late-Stage Trial ViiV Healthcare, majority owned by GlaxoSmithKline plc (NYSE: GSK ), with Pfizer Inc.","NVRO,NVCR",en,Benzinga
2019-08-19 08:14:00-05:00,Here's Why You Should Retain Nevro (NVRO) in Your Portfolio,"Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.",NVRO,en,Zacks Investment Research
2019-08-13 08:08:00-05:00,Nevro (NVRO) Catches Eye: Stock Jumps 6.3%,"Nevro (NVRO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.",NVRO,en,Zacks Investment Research
2019-06-08 08:31:01-05:00,Nevro (NVRO) Down 3.6% Since Last Earnings Report: Can It Rebound?,Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,NVRO,en,Zacks Investment Research
2019-05-20 00:28:19-05:00,Nevro: Opioid-Free Pain Relief - Takeover Coming,No summary available.,NVRO,en,Seeking Alpha
2019-05-13 02:42:00-05:00,"Nevro (NVRO) Q1 Loss Wider Than Expected, Revenues Down Y/Y",Nevro's (NVRO) domestic and international revenues fall year over year in Q1.,NVRO,en,Zacks Investment Research
2019-05-10 15:54:21-05:00,"Notable Friday Option Activity: NVRO, ODFL, BOX",Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Nevro Corp Symbol NVRO where a total of 3 505 contracts have traded so far representing approximately 350 500 underlying shares That amounts to about 56 of NVRO s average,NVRO,en,Nasdaq
2019-05-10 06:44:18-05:00,Nevro down 15% premarket on Q1 miss soft Q2 guidance,"Nevro (NVRO) is down 15% premarket on light volume following its Q1 report issued after the close yesterday. Highlights: Total revenue was $82.1M, down 6%.",NVRO,en,Seeking Alpha
2019-05-10 01:24:01-05:00,Nevro Corp (NVRO) Q1 2019 Earnings Call Transcript,"NVRO earnings call for the period ending March 31, 2019.",NVRO,en,The Motley Fool
2019-05-09 23:34:06-05:00,Nevro Corp (NVRO) CEO Keith Grossman on Q1 2019 Results - Earnings Call Transcript,No summary available.,NVRO,en,Seeking Alpha
2019-05-09 17:25:05-05:00,"Nevro (NVRO) Reports Q1 Loss, Misses Revenue Estimates","Nevro (NVRO) delivered earnings and revenue surprises of -119.70% and -6.09%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?",NVRO,en,Zacks Investment Research
2019-05-09 16:46:57-05:00,"Z, SYMC, PBYI and ANGI among notable after hour movers",No summary available.,NVRO,en,Seeking Alpha
2019-05-09 15:58:21-05:00,"Nevro misses by $0.77, misses on revenue",No summary available.,NVRO,en,Seeking Alpha
2019-05-02 09:33:18-05:00,Analysts Estimate Nevro (NVRO) to Report a Decline in Earnings: What to Look Out for,Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,NVRO,en,Zacks Investment Research
2019-04-17 05:15:00-05:00,"Global Neuromodulation Markets 2019-2024 Featuring Major Players - Medtronic, Boston Scientific, St. Jude Medical, Synapse Biomedical, and Nevro","DUBLIN, April 17, 2019 /PRNewswire/ -- The ""Neuromodulation Market - Growth, Trends, and Forecast (2019 - 2024)"" report has been added to …",NVRO,en,Benzinga
2019-03-21 07:42:53-05:00,Nevro upgraded to overweight from underweight at Morgan Stanley,"This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.",NVRO,en,MarketWatch
2019-03-20 15:29:00-05:00,"Why Chesapeake Energy, Nutanix, and Nevro Jumped Today",Favorable market moves and optimism about the future lifted these stocks.,NVRO,en,The Motley Fool
2019-03-20 11:41:20-05:00,"Nevro's C-Suite, Board Changes Should 'Mark The Turnaround Of The Organization,' BMO Says In Upgrade","Nevro Corp (NYSE: NVRO ) announced a series of board changes and the appointment of a new CEO after the close Tuesday. The medical device company's stock was surging Wednesday on the news. The changes at the helm and to the board come in the wake of pressure from Broadfin Capital, which holds a significant stake in Nevro. The Analyst BMO Capital Markets analyst Joanne Wuensch upgraded Nevro from Market Perform to Outperform and increased the price target from $46 to $67. The Thesis Despite the value of Nevro's franchise, successive downward revisions and management missteps were keeping BMO on the ""While it suspended … Full story available on Benzinga.com",NVRO,en,Benzinga
2019-03-20 10:13:00-05:00,Here's Why Nevro Is Skyrocketing Today,Wall Street cheers after the company announced a surprise change in the corner office. Here's what investors need to know.,NVRO,en,The Motley Fool
2019-03-20 10:04:00-05:00,Cytokinetics and Fibrocell Science among healthcare gainers; Pulmatrix leads the losers,No summary available.,NVRO,en,Seeking Alpha
2019-03-20 09:45:00-05:00,Nevro Soars as New Chief Executive Is Named,"Shares soar after company announces that Keith Grossman, formerly president and CEO of Thoratec, will replace outgoing CEO Rami Eighandour….NVRO",NVRO,en,The Street
2019-03-19 15:52:00-05:00,New chief at Nevro,No summary available.,NVRO,en,Seeking Alpha
2019-03-14 07:01:00-05:00,"Nevro (NVRO) Q4 Loss Wider Than Expected, Revenues Beat",Nevro's (NVRO) solid domestic and international performance aids Q4 results.,NVRO,en,Zacks Investment Research
2019-03-14 02:01:00-05:00,"Nevro (NVRO) Q4 Loss Wider Than Expected, Revenues Beat",Nevro's (NVRO) solid domestic and international performance aids Q4 results.,NVRO,en,Zacks Investment Research
2019-02-22 07:40:50-05:00,Nomura bearish on Xencor in premarket analyst action,No summary available.,NVRO,en,Seeking Alpha
2019-02-21 16:21:11-05:00,"Nevro misses by $0.11, beats on revenue",No summary available.,NVRO,en,Seeking Alpha
2019-02-20 17:35:24-05:00,Nevro Q4 2018 Earnings Preview,No summary available.,NVRO,en,Seeking Alpha
2019-02-15 08:17:11-05:00,Nevro sues Stimwave Technologies for patent infringement,No summary available.,NVRO,en,Seeking Alpha
2019-02-12 11:22:08-05:00,"Medical devices maintain strength, IHI up 11% ytd",No summary available.,NVRO,en,Seeking Alpha
2019-01-23 19:16:23-05:00,Nevro: Upside Via Data Presentations And Product Launches,No summary available.,NVRO,en,Seeking Alpha
2019-01-07 13:33:15-05:00,Nevro (NVRO) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow,No summary available.,NVRO,en,Seeking Alpha
2019-01-07 13:33:15-05:00,Nevro (NVRO) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow,No summary available.,NVRO,en,Seeking Alpha
